Closely held Nimbus Therapeutics is designing and developing precisely tailored small molecule medicines for challenging targets by leveraging a unique strategy that combines computational chemistry technologies with machine learning-based predictive modeling.
Rising Leader Abbas Kazimi’s leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
Abbas Kazimi, CEO of Nimbus Therapeutics, shares his insights about leadership in biopharma and how Nimbus is working to design and develop small molecule medicines capable of improving patients’ lives.
This week, we have conversations with Dr Peter Tummino, president of R&D at Nimbus, and Alex Del Priore, senior vice president, manufacturing at Syngene International Limited.
The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
Nimbus Therapeutics announced the launch of a first-in-human clinical trial for NDI-219216, its investigational Werner syndrome helicase (WRN) inhibitor, targeting microsatellite instability-high (MSI-H) solid tumors. The trial has begun enrolling and dosing participants across multiple clinical sites.
